首页> 外文期刊>The Journal of toxicological sciences >Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy
【24h】

Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy

机译:各种肝毒性化合物诱发凝血病对大鼠肝脏的基因表达谱影响

获取原文
获取原文并翻译 | 示例
           

摘要

A large-scale transcriptome database of rat liver (TG-GATEs) has been established by the Toxicogenomics Project in Japan. In the present study, we focused on 8 hepatotoxic compounds within TG-GATEs, i.e., clofibrate, omeprazole, ethionine, thioacetamide, benzbromarone, propylthiouracil, Wy-14,643 and amiodarone, which induced coagulation abnormalities. Aspirin was selected as a reference compound that directly causes coagulation abnormality, but not through liver toxicity. In blood chemical examinations, for all the coagulopathic compounds there was little elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT), suggesting no severe cell death by treatment with the compounds. We extracted 344 probe sets from the data for these 8 typical drugs, which induced this phenotype at any time from 3 to 28 days of repeated administration. Principal component analysis using these probe sets clearly separated dose- and time-dependent clusters of the treated groups from their controls, except aspirin and propylthiouracil, both of which were considered to cause coagulopathy not due to their hepa-totoxicity but due to their direct effects on the blood coagulation system. Reviewing the extracted genes, changes in lipid metabolism were found to be dominant. Genes related to blood coagulation were generally down-regulated by these drugs except that vitamin K epoxide reductase complex subunit 1 (Vkorcl) like 1, a paralogous gene of Vkorcl, was up-regulated. As expected, expression changes of these genes were least prominent in aspirin or propylthiouracil-treated liver. We concluded that these probe sets could be a good starting point in developing mechanism-based biomarkers for diagnosis or prognosis of hepato-toxicity-related coagulation abnormalities in the early stage of drug development.
机译:日本毒物基因组计划已经建立了大鼠肝转录组数据库(TG-GATE)。在本研究中,我们重点研究了TG-GATEs中的8种肝毒性化合物,即氯贝特,奥美拉唑,乙硫氨酸,硫代乙酰胺,苯溴马隆,丙硫氧嘧啶,Wy-14643和胺碘酮,它们会引起凝血异常。选择阿司匹林作为直接导致凝血异常而不是通过肝毒性的参考化合物。在血液化学检查中,对于所有促凝化合物,天冬氨酸转氨酶(AST)和/或丙氨酸转氨酶(ALT)几乎没有升高,表明用该化合物处理不会导致严重的细胞死亡。我们从这8种典型药物的数据中提取了344个探针集,这些探针在重复给药3至28天的任何时间均可诱导该表型。使用这些探针组进行的主要成分分析清楚地表明,治疗组的剂量和时间依赖性簇与对照组相比分开,但阿司匹林和丙硫尿嘧啶除外,这两种原因均被认为会导致凝血障碍,这不是由于它们的肝毒性而是由于其直接作用在凝血系统上。审查提取的基因,发现脂质代谢的变化占主导。这些药物通常会下调与凝血相关的基因,除了上调维生素K环氧还原酶复合物亚基1(Vkorcl)像1(Vkorcl的同源基因)外。不出所料,这些基因的表达变化在阿司匹林或丙硫氧嘧啶治疗的肝脏中最不明显。我们得出的结论是,这些探针组可能是开发基于机理的生物标志物以在药物开发早期诊断或预后肝毒性相关凝血异常的良好起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号